Standout Papers

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of foll... 2019 2026 2021 2023 296
  1. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study (2019)
    Jan A. Burger, Paul M. Barr et al. Leukemia

Immediate Impact

1 from Science/Nature 55 standout
Sub-graph 1 of 23

Citing Papers

Role of SLC7A11/xCT in Ovarian Cancer
2024 Standout
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
2 intermediate papers

Works of Indu Lal being referenced

Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study
2019

Author Peers

Author Last Decade Papers Cites
Indu Lal 493 355 325 14 746
A. M. Liberati 464 193 352 19 670
Claire Dearden 514 370 353 16 924
Saad M. B. Rassam 483 135 446 15 670
CY Li 340 195 314 12 705
H. Löffler 422 468 330 28 802
James D’Rozario 544 252 386 25 846
Paul Moreton 694 153 634 21 853
Andrew Lipsky 549 200 390 23 671
Esther Rose 611 355 323 21 952
Stephanie R. Brockman 325 257 231 8 827

All Works

Loading papers...

Rankless by CCL
2026